JBC PeproTech; Our Business is Cytokines!

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M305826200 on June 25, 2003

J. Biol. Chem., Vol. 278, Issue 36, 34084-34089, September 5, 2003
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
278/36/34084    most recent
M305826200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Napal, L.
Right arrow Articles by Woldegiorgis, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Napal, L.
Right arrow Articles by Woldegiorgis, G.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

A Single Amino Acid Change (Substitution of the Conserved Glu-590 with Alanine) in the C-terminal Domain of Rat Liver Carnitine Palmitoyltransferase I Increases its Malonyl-CoA Sensitivity Close to That Observed with the Muscle Isoform of the Enzyme*

Laura Napal {ddagger} §, Jia Dai {ddagger} §, Michelle Treber §, Diego Haro ¶, Pedro F. Marrero ¶ and Gebre Woldegiorgis § ||

From the §Department of Environmental and Biomolecular Systems, OGI School of Science & Engineering, Oregon Health & Science University, Beaverton, Oregon 97006-8921 and the Department of Biochemistry and Molecular Biology, University of Barcelona, School of Pharmacy, 08028 Barcelona, Spain

Received for publication, June 3, 2003 , and in revised form, June 18, 2003.


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Carnitine palmitoyltransferase I (CPTI) catalyzes the conversion of long-chain fatty acyl-CoAs to acylcarnitines in the presence of L-carnitine. To determine the role of the highly conserved C-terminal glutamate residue, Glu-590, on catalysis and malonyl-CoA sensitivity, we separately changed the residue to alanine, lysine, glutamine, and aspartate. Substitution of Glu-590 with aspartate, a negatively charged amino acid with only one methyl group less than the glutamate residue in the wild-type enzyme, resulted in complete loss in the activity of the liver isoform of CPTI (L-CPTI). A change of Glu-590 to alanine, glutamine, and lysine caused a significant 9- to 16-fold increase in malonyl-CoA sensitivity but only a partial decrease in catalytic activity. Substitution of Glu-590 with neutral uncharged residues (alanine and glutamine) and/or a basic positively charged residue (lysine) significantly increased L-CPTI malonyl-CoA sensitivity to the level observed with the muscle isoform of the enzyme, suggesting the importance of neutral and/or positive charges in the switch of the kinetic properties of L-CPTI to the muscle isoform of CPTI. Since a conservative substitution of Glu-590 to aspartate but not glutamine resulted in complete loss in activity, we suggest that the longer side chain of glutamate is essential for catalysis and malonyl-CoA sensitivity. This is the first demonstration whereby a single residue mutation in the C-terminal region of the liver isoform of CPTI resulted in a change of its kinetic properties close to that observed with the muscle isoform of the enzyme and provides the rationale for the high malonyl-CoA sensitivity of muscle CPTI compared with the liver isoform of the enzyme.


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Carnitine palmitoyltransferase I (CPTI)1 catalyzes the conversion of long-chain fatty acyl-CoAs to acylcarnitines in the presence of L-carnitine, the first step in the transport of long-chain fatty acids from the cytoplasm to the mitochondria matrix, a rate-limiting step in {beta}-oxidation (1, 2). Mammalian tissues express two isoforms of CPTI, a liver isoform (L-CPTI) and a muscle isoform (M-CPTI), that are 62% identical in amino acid sequence (38). As an enzyme that catalyzes the first rate-limiting step in {beta}-oxidation, CPTI is regulated by its physiological inhibitor, malonyl-CoA (1, 2), the first intermediate in fatty acid synthesis, suggesting a coordinated control of fatty acid oxidation and synthesis. Previous studies by our laboratory and others have demonstrated that the muscle isoform of CPTI, M-CPTI, is significantly more sensitive to malonyl-CoA inhibition than the liver isoform, but the molecular/structural basis for the differences in malonyl-CoA sensitivity between M-CPTI and L-CPTI remain to be established (38). Because of its central role in fatty acid metabolism, understanding the molecular mechanism of the regulation of the CPT system is an important first step in the development of treatments for diseases, such as myocardial ischemia and diabetes, and in human-inherited CPTI deficiency diseases (911).

We developed a novel high level expression system for human heart M-CPTI, rat L-CPTI, and CPTII in the yeast Pichia pastoris, an organism devoid of endogenous CPT activity (6, 1214). Furthermore, by using this system, we have shown that CPTI and CPTII are active distinct enzymes and that L-CPTI and M-CPTI are distinct malonyl-CoA-sensitive CPTs that are reversibly inactivated by detergents. Recent site-directed mutagenesis studies from our laboratory have demonstrated that glutamic acid 3 and histidine 5 in L-CPTI are necessary for malonyl-CoA inhibition and high affinity binding but not for catalysis (15, 16). For M-CPTI, our mutagenesis studies demonstrate that in addition to Glu-3 and His-5, Val-19, Leu-23, and Ser-24 are necessary for malonyl-CoA inhibition and high affinity binding, in agreement with the differences in malonyl-CoA sensitivity observed between M-CPTI and L-CPTI (17, 18). In addition, our site-directed mutagenesis studies of conserved residues in the C-terminal domain of L-CPTI demonstrated that conserved arginine and tryptophan residues are important for catalysis (19). In this report, our mutagenesis studies show for the first time that a change of the highly conserved C-terminal Glu-590 residue in L-CPTI to alanine, glutamine, or lysine significantly increased its sensitivity to malonyl-CoA inhibition.


    EXPERIMENTAL PROCEDURES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
L-CPTI mutants were constructed by the overlap extension PCR procedure using the primers shown in Table I with the wild-type plasmid DNA (pGAP-L-CPTI) as template (12, 20). For example, to construct the E590A mutant, the primers f-GWW3-r-E590A and r-MDR2-f-E590A were used to generate 1.0-kb and 500-bp PCR products, respectively, using the wild-type L-CPTI cDNA as a template. The two PCR products were purified, mixed, and used as a template for a second-round PCR with the primer f-GWW3-r-MDR2. The 1.5-kb PCR product was digested with AvaI-SacI, and the 1.0-kb DNA fragment containing the desired fragment was subcloned into AvaI-SacI-cut wild-type L-CPTI cDNA in the pGAP expression vector. Bacterial colonies obtained upon transformation of the mutagenesis reactions were screened by PCR using the primer pairs f-GWW3-crE590A for Ala, f-GWW3-crE590Q for Gln, f-GWW3-crE590D for Asp, and f-GWW3-crE590A for Lys. The mutations were confirmed by DNA sequencing.


View this table:
[in this window]
[in a new window]
 
TABLE I
PCR primers used for construction of L-CPTI mutants

 

The expression plasmids were linearized by digestion with the restriction enzyme BspEI and integrated into the His-4 locus of P. pastoris GS115 by electroporation (16). Histidine prototrophic transformants were selected on YND plates and grown on YND medium. Mitochondria were isolated by disrupting the yeast cells with glass beads (12) and used to monitor activity and malonyl-CoA sensitivity.

CPT Assay—CPT activity was assayed by the forward exchange method using L-[methyl-3H]carnitine (12, 21). The Km value for palmitoyl-CoA was determined by varying the palmitoyl-CoA concentration from 2.8 to 225 µM at a fixed molar ratio (6.1:1) of palmitoyl-CoA to albumin as described previously (16). The concentration of carnitine was fixed at 200 µM. The Km for carnitine was determined by varying the carnitine concentration from 11 to 472 µM at a fixed 111 µM palmitoyl-CoA concentration.

Western Blot—Proteins were separated by SDS-PAGE in a 10% gel and transferred onto nitrocellulose membranes. Immunoblots were developed by incubation with the L-CPTI-specific antibodies as described previously (16). Sources of other materials and procedures were as described in our previous publication (16)


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Preincubation of isolated mitochondria from the yeast strain expressing rat L-CPTI at room temperature with dicyclohexylcarbodiimide, a glutamate-specific modifying reagent (22), resulted in an irreversible 50% loss in catalytic activity (data not shown). These preliminary chemical modification studies with dicyclohexylcarbodiimide provided evidence that a conserved glutamate residue(s) is important for maximal L-CPTI activity.

Alignment of the sequences of all of the carnitine and choline acyltransferases from different species showed the presence of two conserved glutamate residues, Glu-590 and Glu-603 (Fig. 1). We have previously demonstrated that the conserved Glu-603 residue together with the two adjacent highly conserved arginine residues, Arg-601 and Arg-606, are important for L-CPTI activity and malonyl-CoA sensitivity (19, 23).



View larger version (91K):
[in this window]
[in a new window]
 
FIG. 1.
Sequence alignment of portions of the C-terminal region of various acyltransferases. Asterisk, identical residues; colon, conserved residues.

 

Generation of Mutations and Expression in P. pastoris— Construction of plasmids carrying substitution mutations E590A, E590Q, E590D, and E590K was performed as described under "Experimental Procedures." P. pastoris was chosen as an expression system for L-CPTI and the mutants, because it does not have endogenous CPT activity (6, 1216). The P. pastoris expression plasmids expressed L-CPTI under control of the P. pastoris glyceraldehyde-3-phosphate dehydrogenase gene promoter (12, 24). Yeast transformants with the wild-type L-CPTI gene and the mutants were grown in liquid medium supplemented with glucose (12).

Western blot analysis of wild-type L-CPTI (88 kDa) and the mutants using a polyclonal antibody directed against a maltose-binding protein, L-CPTI fusion protein (12), is shown in Fig. 2, A and B. For the wild type and the mutants E590A, E590Q, E590D, and E590K, proteins of predicted sizes were synthesized with similar steady-state levels of expression.



View larger version (71K):
[in this window]
[in a new window]
 
FIG. 2.
A, immunoblot showing expression of wild type (lane 1), control without insert (lane 2), E590A (lane 3), E590Q (lane 4), E590D (lane 5). B, wild type (lane 1), control without insert (lane 2), E590K (lane 3) mutants in P. pastoris. Mitochondria (20 µg) from the yeast strains expressing the wild type and each of the point mutants were separated on a 10% SDS-PAGE and blotted onto a nitrocellulose membrane. The immunoblot was developed using L-CPTI-specific antibodies as described previously (16).

 

Effect of Mutations on L-CPTI Activity and Malonyl-CoA Sensitivity—Substitution mutant E590D was inactive. A change of Glu-590 to Ala resulted in only a 26% loss in L-CPTI activity, but the mutant E590A exhibited a 16-fold increase in malonyl-CoA sensitivity as shown by the IC50 values in Table II and Fig. 3, A and B. Substitution of Glu-590 with glutamine resulted in a 9-fold increase in malonyl-CoA sensitivity (Table II and Fig. 3B), whereas a change of Glu-590 to Lys resulted in a 53% loss in L-CPTI activity and a 14-fold increase in malonyl-CoA sensitivity (Table II and Fig. 3B). Thus, the partial loss in activity observed with the E590A and E590K mutants was accompanied by a significant increase in sensitivity to malonyl-CoA inhibition compared with the wild-type L-CPTI enzyme (Table II). In short, our studies identify for the first time a conserved residue in the C-terminal region of L-CPTI, Glu-590, which when mutated to neutral and/or positively charged residues is important for increased sensitivity of the enzyme to malonyl-CoA inhibition.


View this table:
[in this window]
[in a new window]
 
TABLE II
CPT activity and malonyl-CoA sensitivity in yeast strains expressing wild-type and mutant L-CPTI

Mitochondria (150 µg of protein) from the yeast strains expressing wild-type L-CPTI, and Glu-590 substitution mutations were assayed for CPT activity and malonyl-CoA sensitivity as described under "Experimental Procedures." The results are the means ± S.D. of at least three independent experiments with different mitochondrial preparations. WT, wild type.

 


View larger version (12K):
[in this window]
[in a new window]
 
FIG. 3.
Effect of increasing concentrations of malonyl-CoA on the activities of yeast-expressed wild-type and mutant L-CPTIs. Approximately 150 µg of mitochondrial protein was used for the assay. A, wild type ({diamondsuit}). B, E590A ({blacktriangleup}), E590K (•), and E590Q ({blacksquare}). RL, rat liver.

 

Kinetic Characteristics of Mutant L-CPTIs—Mutants E590A and E590Q exhibited normal saturation kinetics when the carnitine concentration was varied relative to a constant second substrate, palmitoyl-CoA (Fig. 4A), a property identical to that of the wild-type L-CPTI. For mutants E590A and E590Q, the calculated Km values for carnitine were only 26–48% higher compared with the wild type as shown in Table III. However, the Vmax value for carnitine for the E590A and E590Q mutants was only 14–34% lower compared with the wild-type L-CPTI, indicating no major effect of the mutation on catalytic activity. The catalytic efficiency as estimated by Vmax/Km for E590A and E590Q decreased by 39–45%. With respect to the second substrate, palmitoyl-CoA, mutants E590A and E590Q exhibited normal saturation kinetics similar to the wild type (Fig. 4B) when the molar ratio of palmitoyl-CoA to albumin was fixed at 6.1:1. The calculated Km values for mutants E590A and E590Q were 2- and 2.5-fold lower, and the Vmax values were 58 and 40% lower than the wild type, respectively. For E590A and E590Q, the catalytic efficiency was 63 and 70% lower than the wild type, respectively. Thus, the substitution of the conserved Glu-590 residue with alanine, glutamine, and/or lysine resulted in a reduction in catalytic activity and a significant increase in malonyl-CoA sensitivity. In contrast, a conservative substitution of Glu-590 with aspartate inactivated L-CPTI, suggesting that the longer side chain of glutamate is required for catalytic activity and malonyl-CoA sensitivity.



View larger version (14K):
[in this window]
[in a new window]
 
FIG. 4.
Kinetic analysis of wild-type and mutant L-CPTI activities. Isolated mitochondria (150 µg protein) from the yeast strains expressing the wild type (•), E590A ({blacktriangleup}), and E590Q ({diamondsuit}) mutants were assayed for CPT activity in the presence of increasing concentrations of carnitine (A) and palmitoyl-CoA (B).

 

View this table:
[in this window]
[in a new window]
 
TABLE III
Kinetic characteristics of yeast-expressed wild-type and mutant L-CPTIs

Isolated mitochondria (150 µg of protein) from the yeast strains expressing the wild-type Glu-590 substitution mutations were assayed for CPT activity in the presence of increasing concentrations of carnitine or palmitoyl-CoA. Values are averages of two independent experiments with different mitochondrial preparations. WT, wild type.

 


    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Our site-directed mutagenesis study of the highly conserved Glu-590 residue in the C-terminal region of L-CPTI demonstrated that substitution with alanine, glutamine, or lysine resulted in partial loss in activity and a significant increase in malonyl-CoA sensitivity. Glu-590 and Glu-603 in the C-terminal region of L-CPTI are the only two conserved glutamate residues in the family of acyltransferases (Fig. 1). Glu-603 is a conserved residue within the family of CPT enzymes, whereas other acyltransferases have aspartate at this position. We have recently demonstrated that a change of Glu-603 to alanine or histidine resulted in complete loss in L-CPTI activity (23), whereas a change to glutamine caused a significant loss in activity and malonyl-CoA sensitivity. In contrast with the complete loss of activity observed with the E590D mutant, substitution of Glu-603 with aspartate resulted in only partial loss in CPTI activity but a significant loss in malonyl-CoA sensitivity. A change of the highly conserved glutamate residue corresponding to Glu-590 in CPTII, Glu-487 to aspartate inactivated the enzyme (25), suggesting the importance of this highly conserved residue in CPTI and CPTII in maintaining the active site conformation of the two enzymes. Substitution of the highly conserved Glu-590 with alanine did not have a major effect on catalytic activity but caused a significant increase in L-CPTI malonyl-CoA sensitivity, indicating the opposing roles played by the conserved C-terminal glutamate residues in L-CPTI on activity and malonyl-CoA sensitivity. The site-directed mutagenesis study described here is aimed at elucidating the function of the highly conserved acidic residue, Glu-590, found in the proximity of the active site of L-CPTI.

To determine the role of the highly conserved Glu-590 on catalysis and malonyl-CoA sensitivity, we separately changed the Glu-590 residue to alanine, glutamine, aspartate, and lysine (E590A, E590Q, E603D, and E590K, respectively) and determined the effect of the mutations on L-CPTI activity and malonyl-CoA sensitivity in the yeast-expressed mutant enzyme. A change of Glu-590 to aspartate inactivated L-CPTI. Since a conservative substitution of Glu-590 with aspartate, a negatively charged amino acid with only one methyl group less than the glutamate residue in the wild-type enzyme, resulted in total loss in CPTI activity, the presence of the extra methyl group in Glu-590 is probably crucial for maintaining the configuration of the L-CPTI active site. This finding suggests that a change of Glu-590 to aspartate may result in the carboxylate being outside the hydrogen bond distance of Asp-567, a highly conserved residue that is predicted to be at the CoA binding site of L-CPTI (26). Glu-590 may thus be required for L-CPTI stability and positioning of the imidazole ring of His-473 for efficient catalysis and inhibition, thus facilitating productive interaction with the substrates and the inhibitor (27). The mutant L-CPTIs with a replacement of Glu-590 with alanine (E590A), glutamine (E590Q), and lysine (E590K) showed a partial loss in activity but a significant increase in malonyl-CoA sensitivity. The partial loss in catalytic activity observed with the mutant L-CPTI (E590A, E590Q, and E590K) was in each case associated with a significant increase in malonyl-CoA sensitivity, suggesting that these highly conserved glutamate residues may be important for substrate and inhibitor binding. In contrast, mutation of the corresponding conserved Glu-603 to alanine, histidine, and glutamine resulted in an inactive enzyme or an enzyme with significantly decreased activity and malonyl-CoA sensitivity, suggesting different roles played by these conserved residues in L-CPTI activity and malonyl-CoA sensitivity. The effect of the mutations on activity and malonyl-CoA sensitivity suggest that the highly conserved Glu-590 in the C-terminal region of L-CPTI may be important for substrate (palmitoyl-CoA) and inhibitor (malonyl-CoA) binding, probably through the common CoA moiety present in both compounds. Although there was a decrease in Vmax for both substrates (carnitine and palmitoyl-CoA) with the E590A, E590Q, and E590K mutants, all of the mutants showed an increase in the affinity for palmitoyl-CoA but not carnitine, suggesting that these residues are involved in binding palmitoyl-CoA and malonyl-CoA but not carnitine. Thus, this region may be involved in binding the CoA moiety of palmitoyl-CoA and malonyl-CoA and/or may be the low affinity acyl-CoA binding site.

As a rate-limiting enzyme that transports long-chain fatty acids from the cytosol to the mitochondrial matrix, L-CPTI in the presence of carnitine catalyzes the conversion of long-chain acyl-CoAs to acylcarnitines (1, 2). Similar to other acyltransferases, L-CPTI contains a general acid/base, His-473, a highly conserved amino acid residue that may form a hydrogen-bonding network or a salt bridge to a nearby conserved glutamate residue such as Glu-603 (27). We hypothesize that the substitution of Glu-590 with aspartate may disrupt a hydrogen-bonding network or a salt bridge, perhaps to the highly conserved Asp-567 residue that is predicted to be at the CoA binding pocket of L-CPTI. The hydrogen bonding between the negatively charged carboxyl groups of Glu-590 and Asp-567 may stabilize the positive charge or cation on the carnitine substrate in the wild-type enzyme, but disruption of the hydrogen-bonding network by substitution of Glu-590 with Asp, a negatively charged residue with only one methyl group less than Glu, destabilizes and inactivates L-CPTI. The complete loss in activity in the E590D mutant implicates the important role of Glu-590 in the maintenance of active site architecture, suggesting that substitution of Glu-590 with aspartate may disrupt a hydrogen-bonding network or a salt bridge to a residue like Asp-567 at the substrate binding site pocket of L-CPTI, which may stabilize the positive charge on the carnitine substrate. Disruption of the hydrogen-bonding network due to a change of Glu-590 to Asp may also result in the destabilization of the negative charge on the palmitoyl-CoA substrate due to charge repulsion, thereby inactivating L-CPTI. The substitution of Glu-590 with Gln (E590Q), a neutral residue with the same carbon chain length as Glu, with alanine, a neutral residue with a shorter chain length than Glu, or Lys, a positively charged residue with a longer carbon chain length than Glu, significantly increased the malonyl-CoA sensitivity of L-CPTI with minor change in activity. We suggest that the positive charge in the mutant E590K stabilizes the negative charge on the malonyl-CoA, thus increasing the affinity and sensitivity of the enzyme to the inhibitor, but it may also destabilize the positive charge on the carnitine substrate causing a partial decrease in activity. Because a change of Glu-590 to Gln increased the malonyl-CoA sensitivity of L-CPTI with no effect on activity, we suggest that the negatively charged acidic group of Glu-590 may be responsible for the decreased malonyl-CoA sensitivity of L-CPTI compared with M-CPTI. The role of the negatively charged –COOH group of Glu-590 in the reduction of malonyl-CoA sensitivity of L-CPTI compared with M-CPTI is further supported by our data demonstrating that a change of Glu-590 to Ala, a neutral residue of a much shorter chain length that Glu, significantly enhanced the malonyl-CoA sensitivity of L-CPTI with a partial decrease in activity.

Recent site-directed mutagenesis studies from our laboratory have demonstrated that glutamic acid 3 and histidine 5 in L-CPTI are necessary for malonyl-CoA inhibition and high affinity binding but not for catalysis (15, 16). For M-CPTI, our mutagenesis studies demonstrate that in addition to Glu-3 and His-5, Val-19, Leu-23, and Ser-24 are necessary for malonyl-CoA inhibition and high affinity binding, in agreement with the differences in malonyl-CoA sensitivity observed between M-CPTI and L-CPTI (17, 18). In addition, our site-directed mutagenesis studies of conserved residues in the C-terminal domain of L-CPTI demonstrated that conserved arginine and glutamate residues are important for catalytic activity and malonyl-CoA sensitivity (19, 23). Others have reported that the deletion of N-terminal residues 19–30 containing Ser-24 and Gln-30 or substitution of Ser-24 and Gln-30 with alanine in L-CPTI increased malonyl-CoA sensitivity but their effect was entirely dependent on the presence of Glu-3 because mutation of Glu-3 to alanine was found to override the effects of both the deletion and the combined effects of S24A and Q30A on malonyl-CoA sensitivity (28, 29), confirming our previous report that Glu-3 in the extreme N-terminal region of L-CPTI is the main determinant of malonyl-CoA sensitivity (16).

Mammalian tissues express two isoforms of CPTI, a liver isoform (L-CPTI) and a muscle isoform (M-CPTI), that are 62% identical in amino acid sequence (38). M-CPTI is specifically expressed in heart, skeletal muscle, and testis (6, 8, 30). Previous work from our laboratory and others has shown that M-CPTI has a higher Km for carnitine and an approximately 30-fold lower IC50 for malonyl-CoA (38) inhibition than L-CPTI. In adult heart mitochondria, the total carnitine level is high. Consequently, M-CPTI has a high Km for carnitine but the molecular and/or structural basis for the high malonyl-CoA sensitivity of M-CPTI compared with L-CPTI remains to be established. In this report, we demonstrate that a single substitution of the conserved C-terminal Glu-590 residue to Ala, Gln, and Lys in L-CPTI results in a switch in the kinetic properties of the liver to the muscle isoform of the enzyme because the malonyl-CoA sensitivity of L-CPTI increased to a level close to that observed in M-CPTI. This is the first demonstration of a change in the kinetic properties of the liver isoform of CPTI close to that observed in the muscle isoform of the enzyme by a single site mutation of a conserved negatively charged C-terminal residue to neutral or positively charged residues and forms the structural basis for the high malonyl-CoA sensitivity of M-CPTI compared with L-CPTI.

In this report, we demonstrate that the highly conserved Glu-590 of L-CPTI is required for the structural stability of the enzyme and for the increased sensitivity of L-CPTI to malonyl-CoA inhibition, resulting in a switch in the kinetic property of the liver to the muscle isoform of the enzyme, M-CPTI. Despite its similar charge and potential for hydrogen-bonding formation, aspartate, which has a shorter side chain, cannot substitute for glutamate, suggesting that the extra methyl group of Glu-590 and/or its ability to serve as a strong hydrogen bond acceptor is needed for optimal catalysis, maintenance of active site integrity, and malonyl-CoA inhibition and binding. For the E590D mutant, our data suggest that the loss of a methyl group may result in the carboxylate being outside the hydrogen bond distance of the conserved Asp-567 residue that is at the substrate and/or active site pocket. This finding suggests that the longer side chain of glutamate is essential for substrate binding, catalytic activity, and malonyl-CoA sensitivity. Because only a maximum 16-fold increase in malonyl-CoA sensitivity was observed in these mutants compared with >30-fold higher sensitivity to the inhibitor reported with the wild-type M-CPTI, it is predicted that this C-terminal region may constitute the low affinity malonyl-CoA binding site in L-CPTI (16). Our site-directed mutagenesis study of the only two conserved C-terminal glutamate residues, E590A and E603, in L-CPTI has led to the identification of these residues in L-CPTI that are important for catalytic activity and malonyl-CoA sensitivity. Because a mutation of any of these two conserved C-terminal residues (Glu-590 and Glu-603) substantially decreased catalytic activity and increased (Glu-590) and/or decreased (Glu-603) malonyl-CoA sensitivity, it is hypothesized that these residues are the major contact sites between L-CPTI and the CoA moiety of the substrate (palmitoyl-CoA) and the inhibitor (malonyl-CoA) and constitute the putative low affinity acyl-CoA/malonyl-CoA binding site in L-CPTI.


    FOOTNOTES
 
* This research was supported by National Institutes of Health Grant HL52571 (to G. W.) and a fellowship from the Ministry of Science and Technology of Spain (to L. N.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

{ddagger} Both authors contributed equally to this work. Back

|| To whom correspondence should be addressed: Dept. of Environmental and Biomolecular Systems, OGI School of Science & Engineering, 20000 N. W. Walker Rd., Beaverton, OR 97006-8921. Tel.: 503-748-1676; Fax: 503-748-1464; E-mail: gwoldeg{at}ebs.ogi.edu.

1 The abbreviations used are: CPTI, carnitine palmitoyltransferase I; L-CPTI, liver isoform of CPTI; M-CPTI, muscle isoform of CPTI. Back



    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Bieber, L. L. (1988) Annu. Rev. Biochem. 57, 261–283[CrossRef][Medline] [Order article via Infotrieve]
  2. McGarry, J. D., and Brown, N. F. (1997) Eur. J. Biochem. 244, 1–14[Medline] [Order article via Infotrieve]
  3. Weis, B. C., Esser, V., Foster, D. W., and McGarry, J. D. (1994) J. Biol. Chem. 269, 18712–18715[Abstract/Free Full Text]
  4. Weis, B. C., Cowan, A. T., Brown, N., Foster, D. W., and McGarry, J. D. (1994) J. Biol. Chem. 269, 26443–26448[Abstract/Free Full Text]
  5. Brown, N. F., Weis, B. C., Husti, J. E., Foster, D. W., and McGarry, J. D. (1995) J. Biol. Chem. 270, 8952–8957[Abstract/Free Full Text]
  6. Zhu, H., Shi, J., de Vries, Y., Arvidson, D. N., Cregg, J. M., and Woldegiorgis, G. (1997) Arch. Biochem. Biophys. 347, 53–61[CrossRef][Medline] [Order article via Infotrieve]
  7. Yamazaki, N., Shinhara, Y., Shima, A., and Terada, H. (1995) FEBS Lett. 363, 41–45[CrossRef][Medline] [Order article via Infotrieve]
  8. Yamazaki, N., Shinhara, Y., Shima, A., Yamanaka, Y., and Terada, H. (1996) Biochim. Biophys. Acta 1307, 157–161[Medline] [Order article via Infotrieve]
  9. Prentki, M., and Corkey, B. E. (1996) Diabetes 45, 273–283[Abstract]
  10. Corr, P. B., and Yamada, K. A. (1995) Herz 20, 156–168[Medline] [Order article via Infotrieve]
  11. Bennefont, J. P., Taroni, F., Cavadini, P., Cepanec, C., Brivet, M., Saudubray, J. M., Leroux, J. P., and Demaugre, F. (1996) Am. J. Hum. Genet. 58, 971–978[Medline] [Order article via Infotrieve]
  12. de Vries, Y., Arvidson, D. N., Waterham, H. R., Cregg, J. M., and Woldegiorgis, G. (1997) Biochemistry 36, 5285–5292[CrossRef][Medline] [Order article via Infotrieve]
  13. Zhu, H., Shi, J., Cregg, J. M., and Woldegiorgis, G. (1997) Biochem. Biophys. Res. Commun. 239, 498–502[CrossRef][Medline] [Order article via Infotrieve]
  14. Woldegiorgis, G., Shi, J., Zhu, H., and Arvidson, D. N. (2000) J. Nutr. 130, (suppl.) 310–314[Abstract/Free Full Text]
  15. Shi, J., Zhu, H., Arvidson, D. N., Cregg, J. M., and Woldegiorgis, G. (1998) Biochemistry 37, 11033–11038[CrossRef][Medline] [Order article via Infotrieve]
  16. Shi, J., Zhu, H., Arvidson, D. N., and Woldegiorgis, G. (1999) J. Biol. Chem. 274, 9421–9426[Abstract/Free Full Text]
  17. Shi, J., Zhu, H., Arvidson, D. N., and Woldegiorgis, G. (2000) Biochemistry 39, 712–717[CrossRef][Medline] [Order article via Infotrieve]
  18. Zhu, H., Shi, J., Treber, M., Dai, J., Arvidson, D., and Woldegiorgis, G. (2003) Arch. Biochem. Biophys. 413, 67–74[Medline] [Order article via Infotrieve]
  19. Dai, J., Zhu, H., Shi, J., and Woldegiorgis, G. (2000) J. Biol. Chem. 275, 22020–22024[Abstract/Free Full Text]
  20. Tao, B. Y., and Lee, K. C. P. (1994) in PCR Technology: Current Innovations (Griffin, H. G., and Griffin, A. M., eds) pp. 69–83, CRC Press, Inc., Boca Raton, FL
  21. Bremer, J., Woldegiorgis, G., Schalinske, K., and Shrago, E. (1985) Biochim. Biophys. Acta 833, 9–16[Medline] [Order article via Infotrieve]
  22. Harrison, M., Powell, B., Finbow, M. E., and Findlay, J. B. C. (2000) Biochemistry 39, 7531–7537[CrossRef][Medline] [Order article via Infotrieve]
  23. Treber, M., Dai, J., and Woldegiorgis, G. (2003) J. Biol. Chem. 278, 11145–11149.[Abstract/Free Full Text]
  24. Waterham, H. R., Digan, M. E., Koutz, P. J., Lair, S. V., and Cregg, J. M. (1997) Gene (Amst.) 16, 37–44
  25. Zheng, G., Dai, J., and Woldegiorgis, G. (2002) J. Biol. Chem. 277, 42219–42223[Abstract/Free Full Text]
  26. Jogl, G., and Tong, L. (2003) Cell 112, 113–122[CrossRef][Medline] [Order article via Infotrieve]
  27. Barycki, J. J., O'Brien, L. K., Strauss, A. W., and Banaszaki, L. J. (2001) J. Biol. Chem. 276, 36718–36726[Abstract/Free Full Text]
  28. Jackson, V. N., Zammit, V. A., and Price, N. T. (2000) J. Biol. Chem. 275, 38410–38416[Abstract/Free Full Text]
  29. Jackson, V. N., Price, N. T., and Zammit, V. A. (2001) Biochemistry 40, 14629–14634[CrossRef][Medline] [Order article via Infotrieve]
  30. Adams, S. H., Esser, V., Brown, N. F., Ing, N. H., Johnson, L., Foster, D. W., and McGarry, J. D. (1998) Biol. Reprod. 59, 1399–13405[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Physiol.Home page
G. P. Holloway, V. Bezaire, G. J. F. Heigenhauser, N. N. Tandon, J. F. C. Glatz, J. J. F. P. Luiken, A. Bonen, and L. L. Spriet
Mitochondrial long chain fatty acid oxidation, fatty acid translocase/CD36 content and carnitine palmitoyltransferase I activity in human skeletal muscle during aerobic exercise
J. Physiol., February 15, 2006; 571(1): 201 - 210.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
N. Yang, J. S. Kays, T. R. Skillman, L. Burris, T. W. Seng, and C. Hammond
C75 [4-Methylene-2-octyl-5-oxo-tetrahydro-furan-3-carboxylic Acid] Activates Carnitine Palmitoyltransferase-1 in Isolated Mitochondria and Intact Cells without Displacement of Bound Malonyl CoA
J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 127 - 133.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
D. W. FOSTER
The Role of the Carnitine System in Human Metabolism
Ann. N.Y. Acad. Sci., November 1, 2004; 1033(1): 1 - 16.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
G. JOGL, Y.-S. HSIAO, and L. TONG
Structure and Function of Carnitine Acyltransferases
Ann. N.Y. Acad. Sci., November 1, 2004; 1033(1): 17 - 29.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Kerner, A. M. Distler, P. Minkler, W. Parland, S. M. Peterman, and C. L. Hoppel
Phosphorylation of Rat Liver Mitochondrial Carnitine Palmitoyltransferase-I: EFFECT ON THE KINETIC PROPERTIES OF THE ENZYME
J. Biol. Chem., September 24, 2004; 279(39): 41104 - 41113.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
278/36/34084    most recent
M305826200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Napal, L.
Right arrow Articles by Woldegiorgis, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Napal, L.
Right arrow Articles by Woldegiorgis, G.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2003 by the American Society for Biochemistry and Molecular Biology.